MX2021015095A - Construcciones de proteínas de unión a antígenos y usos de estos. - Google Patents

Construcciones de proteínas de unión a antígenos y usos de estos.

Info

Publication number
MX2021015095A
MX2021015095A MX2021015095A MX2021015095A MX2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A
Authority
MX
Mexico
Prior art keywords
antigen
binding protein
protein constructs
binding
dll3
Prior art date
Application number
MX2021015095A
Other languages
English (en)
Inventor
Alexander J Nichols
Brian P Fiske
Nimish Gera
Original Assignee
Mythic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mythic Therapeutics Inc filed Critical Mythic Therapeutics Inc
Publication of MX2021015095A publication Critical patent/MX2021015095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se proporcionan construcciones de proteínas de unión a antígenos capaces de unirse específicamente a DLL3 o un epítopo de DLL3 presente en la superficie de una célula de mamífero diana, en el que dicha unión a antígeno depende del pH. También se proporcionan usos de dicha construcciones de proteínas de unión a antígenos.
MX2021015095A 2019-06-07 2020-06-05 Construcciones de proteínas de unión a antígenos y usos de estos. MX2021015095A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858932P 2019-06-07 2019-06-07
US201962888384P 2019-08-16 2019-08-16
PCT/US2020/036495 WO2020247873A1 (en) 2019-06-07 2020-06-05 Antigen-binding protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
MX2021015095A true MX2021015095A (es) 2022-03-22

Family

ID=71899864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015095A MX2021015095A (es) 2019-06-07 2020-06-05 Construcciones de proteínas de unión a antígenos y usos de estos.

Country Status (9)

Country Link
US (1) US20220313845A1 (es)
EP (1) EP3980129A1 (es)
JP (1) JP2022535452A (es)
CN (1) CN114746115A (es)
AU (1) AU2020289477A1 (es)
CA (1) CA3142884A1 (es)
IL (1) IL288685A (es)
MX (1) MX2021015095A (es)
WO (1) WO2020247873A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107901A1 (en) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2024012524A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法

Also Published As

Publication number Publication date
CN114746115A (zh) 2022-07-12
JP2022535452A (ja) 2022-08-08
WO2020247873A1 (en) 2020-12-10
AU2020289477A1 (en) 2022-02-03
US20220313845A1 (en) 2022-10-06
IL288685A (en) 2022-02-01
EP3980129A1 (en) 2022-04-13
CA3142884A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
MX2022001286A (es) Construcciones de proteínas de unión a antígenos y usos de estas.
MX2020012927A (es) Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
EP3826612A4 (en) NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
MX2020009774A (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
AU2018318303A1 (en) Antigen-binding proteins targeting shared antigens
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof
MX2021015095A (es) Construcciones de proteínas de unión a antígenos y usos de estos.
MX2019009346A (es) Variantes de polipeptidos y usos de los mismos.
WO2021055765A3 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2019242632A8 (en) Engineered cells and uses thereof
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
EP3966252A4 (en) HUMANIZED ANTI-CD137 ANTIBODIES AND THEIR USES
PH12020552181A1 (en) Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
EP4056586A4 (en) REGULATORY T CELL SURFACE ANTIGEN EPITOPE, AND ANTIBODIES BINDING SPECIFICALLY THEREFOR
EP3915581A4 (en) NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
WO2020010079A3 (en) Anti-steap1 antigen-binding protein
TWI799855B (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN
EP3798227A4 (en) EPITOPE OF A REGULATORY T-CELL SURFACE ANTIGEN AND ANTIBODY SPECIFIC BINDING TO IT